Apoeε4 Carriership Combined With Aβ Positivity For Ad Clinical Trial Enrichment

APOEε4 carriership combined with Aβ positivity for AD clinical trial enrichment

Significance of ALZ-801’s Impact on Carriers of APOE e4 Alleles

APOE4 and Alzheimer's Risk - BrainMind Alzheimer's Prevention Series

BrainMind Summit

The PreventE4 study: testing omega-3 supplementation in APOE4 carriers before the onset of dementia

PFSD2020: Interactive Effect of APOE ε4 and Sex Potentiates Early Tau Deposition in Women

Optimized anti-Aβ vaccination enters clinical trials in Alzheimer's disease

A new Aβ PET-based staging method

Clinical trial for BAN2401 in early Alzheimer’s: combining ADCOMS and Bayesian statistics

Important considerations for APOE disclosure in AD risk assessment

Build Better Clinical Trial Outreach Materials

National Institute on Aging

Why Clinical Trials for Alzheimer’s Fail?

Endpoints in AD clinical trials: The Functional Activities Questionnaire (Richard Isaacson)

Exploring Alzheimer’s Disease Together

What’s next for clinical trials in Alzheimer’s disease?

Endpoints in AD clinical trials: The Quality of Life in Alzheimer’s Disease (Richard Isaacson)

Exploring Alzheimer’s Disease Together

Using a p-tau217 assay to screen participants for the ALTITUDE-AD trial

Biomarkers for early detection of Alzheimer’s disease: microRNAs

Phase II trial of XPro1595 for the treatment of Alzheimer’s disease

Endpoints in AD clinical trials: The Alzheimer’s Disease Assessment Scale–Cognitive Subscale

Exploring Alzheimer’s Disease Together

The Key Genetic Factor in Alzheimer's: APOE4 Gene 🧬🧠